KOSDAQBiotech & Pharma175250

Icure Pharmaceutical Incorporation

₩1,375▼ 3.10%2026-11-18 close
Market Cap
₩84.9B
Turnover
₩52,296,979
Volume
40K
Shares out.
61.7M
PER
—
PBR
1.0×
EPS
-₩383
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Operating profit up two straight quarters after turning positive

Icure's operating profit has risen for two straight quarters since it turned positive in the first quarter of 2026, but a 270.0% debt ratio at end-2025 and a patch manufacturing suspension starting November 18, 2026 remain open issues.

  1. 1

    Revenue reached KRW 83.4 billion in 2025, the largest year of 2022 to 2025, and rose in both 2024 and 2025.

  2. 2

    Third-quarter 2026 revenue was KRW 35.2 billion, up 40.0% year on year, and operating profit of KRW 3.7 billion turned a year-earlier operating loss into a profit.

  3. 3

    The 2025 net loss attributable to controlling shareholders was KRW 33.6 billion, and the last four quarters total a KRW 14 billion loss, while the second and third quarters of 2026 each posted a profit of about KRW 2.3 billion.

  4. 4

    Cosmetics ODM sales growth drove results, while the pharmaceutical unit showed growth in its patch CDMO business and a smaller operating loss.

  5. 5

    A 15-day manufacturing suspension for patch products applies from November 18 to December 2, 2026, and the company has said it expects no impact on sales.

02

Business structure

Icure operates a cosmetics contract manufacturing (ODM) business and a pharmaceutical business built on transdermal drug delivery technology.

Cumulative third-quarter 2026 separate-basis sales were KRW 91.75 billion for cosmetics ODM and KRW 13.18 billion for pharmaceuticals, so most revenue comes from cosmetics ODM (company results announcement, November 17, 2026).

The main cosmetics ODM product lines are hydrogel mask packs, sheet mask packs, basic skincare products and patch products. The company said it dissolved an affiliated Cosmax Icure entity and has produced hydrogel mask packs in-house since 2025.

First-quarter 2026 cosmetics ODM sales were KRW 27.6 billion, up 145.5% year on year, and the company attributed the growth mainly to new clients such as the K-beauty company APR. The core of the pharmaceutical business is patch CDMO, where first-quarter 2026 sales were KRW 4.3 billion, up 62.7% year on year.

Total pharmaceutical sales in the same quarter fell 8.0% to KRW 4.5 billion, which the company explained as a change in revenue recognition after it shifted its prescription drug (ETC) business toward distributors.

The pharmaceutical operating loss in the first quarter of 2026 narrowed to KRW 800 million from KRW 3.17 billion a year earlier. Because cosmetics ODM revenue follows client orders, client concentration and the pace of new client wins are key variables.

The pharmaceutical unit is moving on two tracks at once: patch CDMO growth and a restructuring of oral prescription sales.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩25.1B-₩3.3B−13.0%
2025Q4₩10.9B-₩1.8B−17.0%
2026Q1₩32.2B₩200M0.6%
2026Q2₩37.7B₩2.4B6.4%
2026Q3₩35.2B₩3.7B10.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩59.4B-₩26.8B-₩41.8B−45.1%−46.6%144.0%
2023₩56.8B-₩22.7B-₩31.4B−39.9%−54.0%178.8%
2024₩69.2B-₩17.2B₩1B−24.8%1.7%118.8%
2025₩83.4B-₩12B-₩33.6B−14.3%−127.5%270.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue was KRW 59.4 billion in 2022, KRW 56.8 billion in 2023 (down 4.3% year on year), KRW 69.2 billion in 2024 (up 21.8%) and KRW 83.4 billion in 2025 (up 20.5%). Revenue rose in 2024 and 2025 after the 2023 low, and 2025 was the largest year of 2022 to 2025.

Operating losses of KRW 26.8 billion, KRW 22.7 billion, KRW 17.2 billion and KRW 12 billion in 2022 to 2025 mark four straight years of losses, while the operating margin improved from -45.1% to -14.3%.

Net loss attributable to controlling shareholders was KRW 41.8 billion in 2022 and KRW 31.4 billion in 2023, turned to a KRW 1.05 billion profit in 2024, and returned to a KRW 33.6 billion loss in 2025. Net income including non-controlling interests was KRW 24.73 million in 2024 and a KRW 34.5 billion loss in 2025.

Quarterly revenue fell from KRW 25.1 billion in the third quarter of 2025 to KRW 10.9 billion in the fourth quarter, then rose to KRW 32.2 billion in the first quarter of 2026, KRW 37.7 billion in the second quarter and KRW 35.2 billion in the third quarter.

Operating profit turned to a KRW 208 million profit in the first quarter of 2026 after losses of KRW 3.26 billion and KRW 1.84 billion in the prior two quarters, then rose to KRW 2.4 billion and KRW 3.7 billion.

The net loss attributable to controlling shareholders widened to KRW 18.1 billion in the fourth quarter of 2025 from KRW 3.7 billion in the third quarter.

One-off items include a partial sales discount in the first quarter of 2026, applied while the company accelerated collections from some clients, and KRW 130 million of non-recurring costs, including legal fees linked to a former CEO, which the company excluded in its separate-basis adjusted figures.

On the balance sheet, the debt ratio at end-2025 was 270.0%, up from 118.8% in 2024, while operating cash outflow narrowed to KRW 2.68 billion from KRW 17.1 billion.

05

Industry analysis

The cosmetics ODM business is structured so that quarterly revenue moves sharply with client order flow. Reported results show this, with revenue moving from KRW 10.9 billion in the fourth quarter of 2025 to KRW 32.2 billion in the first quarter of 2026.

The company said it dissolved an affiliated entity and has brought hydrogel mask pack production in-house since 2025. This ties into the expansion of K-beauty brand clients, so demand for basic product lines such as mask packs is a key driver.

In pharmaceuticals, the patch CDMO business, which handles transdermal formulations, grew 62.7% to KRW 4.3 billion in the first quarter of 2026, showing rising demand for contract manufacturing. The oral prescription drug business is being restructured around distributors, which changed how revenue is recognized.

Compared with CDMO-focused Samsung Biologics, Icure's patch CDMO is a small business in transdermal formulations.

Unlike companies valued mainly on drug pipelines, Icure's revenue centers on cosmetics ODM and contract manufacturing, so the more relevant benchmark is the pace of operating margin improvement rather than scale.

Competition in cosmetics ODM depends on client wins and production capacity, and the company's in-house mask pack production is cited as a point of differentiation.

06

Outlook

The nearest checkpoint is the patch manufacturing suspension. The order disclosed on November 6, 2026 runs 15 days from November 18 to December 2, 2026, with a disclosed suspended amount of about KRW 13.89 billion, equal to 16.77% of recent total sales.

The company said it expects no impact on sales from this suspension. In its November 17, 2026 announcement, cumulative third-quarter separate-basis sales were KRW 104.93 billion and operating profit was KRW 6.57 billion.

The same release said cumulative sales rose 78.6% year on year and that operating profit and net income turned positive. Reports said a KRW 25 billion rights offering was completed, and later filings will show how the proceeds are used for debt repayment or operations.

The pharmaceutical unit is shifting oral prescription sales toward distributors, so quarterly revenue mix may keep changing. Whether patch CDMO growth continues will determine the pace of pharmaceutical profit improvement.

The company said it reached the operating profit turnaround in the first quarter of 2026, a goal set when the current CEO took office in 2022. The 2026 annual report, the next regular filing, will include fourth-quarter 2026 results and confirmed full-year figures.

07

Valuation

PER
—
PBR
1.0×
ROE
-27.8%
EPS
-₩383
BPS
₩1,356
Dividend per share
₩0

The price-to-book ratio places the market price close to the book value of equity attributable to controlling shareholders. This reflects a capital base that shrank after years of losses, so the pace at which equity recovers is the benchmark for valuation comparison.

The four-quarter net loss attributable to controlling shareholders totals KRW 14 billion, so a price-to-earnings ratio cannot be calculated on that basis.

Net profit attributable to controlling shareholders turned positive in the second and third quarters of 2026, but the last four quarters still include losses, which limits earnings-based comparison. The dividend yield is low, consistent with a company that has been posting losses.

The debt ratio of 270.0% at end-2025 shapes how the capital structure weighs on valuation. Whether profit continues after operating profit moved into the black is the variable that could change the premium the market places on the same asset base.

Comparison with past valuation bands is only meaningful when read alongside the timing of the shift from losses to profits.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Operating profit up two straight quarters

Operating profit turned to a KRW 208 million profit in the first quarter of 2026, then rose to KRW 2.4 billion and KRW 3.7 billion. Third-quarter 2026 revenue was KRW 35.2 billion, up 40.0% year on year, and operating profit moved from a KRW 3.26 billion loss in the third quarter of 2025 to a profit.

Net income attributable to controlling shareholders stayed positive at KRW 2.32 billion in the second quarter and KRW 2.31 billion in the third.

Narrower pharmaceutical losses

According to the company's separate-basis first-quarter 2026 release, the pharmaceutical operating loss narrowed to KRW 800 million from KRW 3.17 billion a year earlier. Patch CDMO sales rose 62.7% to KRW 4.3 billion.

The company attributed the overall decline in pharmaceutical sales to a change in revenue recognition after shifting its oral prescription business toward distributors.

Smaller operating cash outflow and capital raise

Operating cash outflow narrowed to KRW 2.68 billion in 2025 from KRW 17.1 billion in 2024. Reports dated November 17, 2026 said a KRW 25 billion rights offering was completed, adding to the capital base. Whether operating cash generation continues will matter for reducing the debt burden.

09

Bear factors

Accumulated losses attributable to controlling shareholders

The 2025 net loss attributable to controlling shareholders was KRW 33.6 billion, and it widened to KRW 18.1 billion in the fourth quarter. The last four quarters total a KRW 14 billion loss, and the profits of the second and third quarters of 2026 have not yet offset that cumulative amount. Net income including non-controlling interests was a KRW 34.5 billion loss in 2025.

Balance sheet pressure

At end-2025, total equity was KRW 24.5 billion, of which equity attributable to controlling shareholders was KRW 26.3 billion, and total liabilities were KRW 66 billion. The debt ratio rose to 270.0% in 2025 from 118.8% in 2024.

With debt large relative to equity, financing costs and dependence on operating cash generation could remain a burden.

Pharmaceutical sales decline and continued losses

First-quarter 2026 pharmaceutical sales were KRW 4.5 billion, down 8.0% year on year, and the unit still posted an operating loss of KRW 800 million. The shift of the oral prescription business toward distributors is changing the sales mix, so total pharmaceutical revenue may move differently from quarter to quarter. The pharmaceutical unit has not yet reported a turn to profit.

10

Risk factors

Regulatory and administrative risk

The 15-day patch manufacturing suspension disclosed on November 6, 2026 applies from November 18 to December 2, 2026. The disclosed suspended amount is about KRW 13.89 billion, equal to 16.77% of recent total sales.

The company expects no sales impact, but whether clients shift orders during the suspension will appear in later results.

Collection and revenue recognition risk

In the first quarter of 2026, the company accelerated collections from some clients by one month and applied a partial sales discount. The company said this was part of arranging funds for a withholding tax payment.

Because the oral prescription business changed its revenue recognition after the shift to distributors, quarterly revenue comparability has also weakened.

One-off costs and governance change

According to the company's separate-basis first-quarter 2026 release, non-recurring costs of KRW 130 million were incurred, including legal costs tied to a former CEO. With the completion of a KRW 25 billion rights offering reported, share count and ownership structure may change. Further legal disputes or costs could again move quarterly results.

11

What to watch next

  1. December 2, 2026

    The day the patch manufacturing suspension ends. The next filings will show the sales trend afterward and whether the expected absence of sales impact holds.

  2. Within Q1 2027 (date not set)

    Whether and when fourth-quarter 2026 preliminary results are released. The check is how fourth-quarter net profit or loss attributable to controlling shareholders compares with the KRW 18.1 billion loss in the fourth quarter of 2025.

  3. Around late March 2027 (statutory filing deadline)

    The filing of the 2026 annual report. It will add fourth-quarter 2026 results and confirmed full-year sales, operating profit and net income attributable to controlling shareholders to the disclosed record.

  4. Early 2027 onward (date not set)

    Whether patch CDMO growth and the distributor shift in oral prescriptions show up in pharmaceutical profit and loss. The observation point is whether the KRW 800 million first-quarter 2026 pharmaceutical operating loss narrows further.

12

Overall view

Icure's reported results show revenue rising in 2024 and 2025 to KRW 83.4 billion in 2025, the largest year of 2022 to 2025. Operating losses ran for four straight years through 2025, but the operating margin narrowed from -45.1% to -14.3%.

In 2026, operating profit turned positive in the first quarter and rose in the second and third quarters, and third-quarter revenue was up 40.0% year on year.

On the other side, the last four quarters carry a cumulative KRW 14 billion net loss attributable to controlling shareholders, and the debt ratio at end-2025 was a high 270.0%.

The pharmaceutical unit is pursuing patch CDMO growth alongside a shift in oral prescriptions toward distributors, and the patch manufacturing suspension runs from November 18 to December 2, 2026.

Strengths such as sustained operating profit and weaknesses such as accumulated net losses and financial burden both remain in view. The next checkpoints are sales after the suspension ends and the confirmed full-year results in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. seoul.co.kr
  2. supple.kr
  3. news.nate.com
  4. m.news.nate.com
  5. kormedi.com
  6. news.nate.com
  7. comp.fnguide.com
  8. m.jobkorea.co.kr
  9. jobplanet.co.kr
  10. specialtimes.co.kr
  11. mt.co.kr
  12. newsway.co.kr
  13. supple.kr
  14. msn.com
  15. msn.com
  16. etnews.com
  17. sportalkorea.com
  18. news.nate.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis